Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to 9978.33%.

  • Cardiff Oncology's EBITDA Margin fell 23413600.0% to 9978.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 10719.56%, marking a year-over-year decrease of 39835700.0%. This contributed to the annual value of 7123.13% for FY2024, which is 21826000.0% up from last year.
  • Per Cardiff Oncology's latest filing, its EBITDA Margin stood at 9978.33% for Q3 2025, which was down 23413600.0% from 12212.4% recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's EBITDA Margin ranged from a high of 5333.17% in Q1 2024 and a low of 14964.86% during Q1 2022
  • Over the past 5 years, Cardiff Oncology's median EBITDA Margin value was 8325.83% (recorded in 2024), while the average stood at 9522.92%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 91873100bps in 2024, then tumbled by -78613200bps in 2025.
  • Cardiff Oncology's EBITDA Margin (Quarter) stood at 7162.41% in 2021, then fell by -2bps to 7337.5% in 2022, then increased by 10bps to 6623.08% in 2023, then fell by -26bps to 8325.83% in 2024, then fell by -20bps to 9978.33% in 2025.
  • Its last three reported values are 9978.33% in Q3 2025, 12212.4% for Q2 2025, and 13194.5% during Q1 2025.